Search Bar & Filters
Found 482 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the performance of PathFinder 1.0, a software designed to detect retinal abnormalities using macular cube OCT B-scans. The study aims to measure how accurately PathFinder 1.0 identifies these abnormalities by assessing its sensitivity and specificity. This diagnostic study includes adults 18 years and older with and without macular abnormalities in the central macula area. Participants will undergo standard OCT imaging using CIRRUS HD-OCT systems. The investigational PathFinder 1.0 software will analyze these images to detect macular abnormalities without affecting clinical care. The study groups include subjects without any macular abnormalities and those with various retinal changes such as vitreoretinal interface disruption, hyporeflective spaces, ISOS disruption, and retinal pigment epithelium changes. During a single study visit, participants will have ophthalmic imaging performed to collect data for analysis. Researchers will evaluate sensitivity, specificity, predictive values, scan quality, and the softwares repeatability based on these images. Participants must be able to complete imaging and follow study instructions. The total participation involves one visit with no additional follow-up. Safety and image quality will be monitored throughout the trial.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Healthy Volunteer
Many people experience wounds that do not heal well or take a long time to heal, including both chronic and acute wounds. This research aims to study the effects of 4-aminopyridine 4-AP, a drug currently used in neurological conditions, to see if it can help speed up wound healing in healthy adults. Previous animal studies showed promising results with faster healing and no adverse effects, making it important to evaluate 4-APs role in human wound repair. Participants in this study will be randomly assigned to receive either 4-aminopyridine capsules or placebo capsules taken every 12 hours. The treatment period lasts for 6 weeks, during which researchers will monitor wound healing progress. The study includes a phase where participants receive either the active drug or placebo to compare effects on skin integrity and wound closure. During the study, participants will have a skin punch biopsy wound that will be monitored for healing over 6 weeks. Researchers will assess the return of skin integrity, wound closure, and hair growth at the biopsy site. Participants must attend scheduled follow-up visits and may be asked to provide wound photographs. The study also tracks safety and tolerability, ensuring participants are able to report any sensory or motor changes. Total participation is about 6 weeks with regular evaluations.
Actively Recruiting
Many patients suffer from traumatic burns, and current treatments mainly focus on infection prevention and fluid management without improving the skins ability to regenerate. This research aims to evaluate the role of 4-aminopyridine 4-AP, a promising agent with a good safety profile, in accelerating burn wound healing in patients with second-degree burns. The study addresses the need for new regenerative treatments that can speed up recovery while allowing existing protocols to continue. Participants will be randomly assigned to receive either 4-aminopyridine capsules 10 mg every 12 hours or a placebo capsule on the same schedule. This phase 2 study will compare these two groups over a 12-month period to assess the treatments effect on the healing process. The study uses triple masking to ensure unbiased results. During the study, participants will be monitored for healing rate, skin graft requirements, scar formation, and scar sensitivity over 12 months. They will provide informed consent and attend scheduled follow-up visits where researchers will evaluate wound healing through sensory and motor assessments and calibrated wound photographs. Safety and adherence will be closely tracked to evaluate the treatments impact and patient outcomes throughout the study period.
Actively Recruiting
Researchers are studying the potential effects of 4-aminopyridine 4-AP on recovery after peripheral nerve injuries caused by traction or crush. The study focuses on men with prostate cancer undergoing robot-assisted radical prostatectomy, as nerve injury during this surgery may lead to erectile dysfunction and urinary continence issues. This research aims to test whether 4-AP can speed up the often slow and unpredictable recovery process after such nerve injuries. Participants will receive either FDA-approved 10 mg 4-aminopyridine tablets or placebo tablets after surgery. The medication is taken orally, with a maximum of two tablets per 24 hours, and must be swallowed whole without breaking or crushing. The treatment period lasts for 60 days following surgery. The placebo is designed to look like the active drug, and participants will be reminded not to take other aminopyridine medications during the study. Throughout the study, participants will be monitored for changes in urinary incontinence and erectile function using standardized questionnaires every seven days for six months. They will also keep a daily drug diary for 90 days and complete sexual activity questionnaires regularly. The study includes follow-up for up to one year to assess recovery progress and safety. The total participation time involves regular assessments and monitoring after the surgery.
Actively Recruiting
Researchers are evaluating the role of a single dose of 4-aminopyridine 4-AP to help diagnose whether nerve injuries from peripheral nerve traction or crush are complete or incomplete. The study aims to speed up the identification of nerve continuity compared to standard electrodiagnostic and clinical assessments. This is a phase 2, randomized, double-blind crossover trial conducted at a single center. Participants will be randomized to receive either a 10 mg dose of 4-aminopyridine followed by a placebo, or placebo followed by the drug, with the order determined randomly. Each participant undergoes baseline sensory and motor testing, blood sampling, and then hourly testing for three hours after each dose to assess sensory and motor function, electrodiagnostic results, and serum 4-AP levels. After completing both treatment arms, testing concludes. Following initial testing, participants will be monitored for 20 weeks with follow-up visits at 2, 6, 12, 18, and 20 weeks, including physical exams and phone interviews at 9 and 15 weeks to assess subjective motor and sensory function. The main outcome measured is the subjective return of sensation during dosing and at various post-injury time points. Each visit or call lasts about 30 minutes.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and early effects of 4D-710, an investigational gene therapy, in adults with cystic fibrosis CF lung disease who cannot use or tolerate existing CFTR modulator therapies. A sub-study also includes adults with advanced CF lung disease or frequent lung flare-ups who are currently on CFTR modulator therapy. This Phase 12 open-label trial aims to find appropriate dosing and assess potential benefits for these patient groups. Participants receive a single inhaled dose of 4D-710, which is a gene therapy designed to deliver a corrected version of the CFTR gene to lung cells. The study includes a dose exploration phase for those ineligible for modulator therapy, a dose expansion phase at selected doses, and a sub-study for participants on modulator therapy receiving various doses. Each participant undergoes one administration of the therapy during the trial. Throughout the study, participants are monitored for adverse events over a 60-month period. Evaluations include lung function tests, oxygen saturation measurements, and tracking of pulmonary exacerbations. Participants maintain their existing treatments if applicable, and researchers assess safety and early signs of effectiveness. The total study duration extends up to approximately nine years, including long-term observation after dosing.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are investigating treatments for hormone receptor-positive and HER2-negative breast cancer that is either locally advanced and cannot be removed by surgery or has spread to other body parts. The study focuses on comparing patritumab deruxtecan with chemotherapy or trastuzumab deruxtecan to see if patients live longer or have delayed cancer progression. This phase 3 trial evaluates these treatments in people who have had prior progression on CDK46 inhibitor plus endocrine therapy. Participants receive either patritumab deruxtecan through intravenous infusion every three weeks for about 13 months or treatment chosen by their doctor, which may include various chemotherapy drugs or trastuzumab deruxtecan up to 13 months. Treatments are given in cycles with specific dosing schedules depending on the drug selected. Rescue medications are also allowed as needed following approved guidelines. During the study, participants undergo regular assessments including scans to measure disease progression and evaluations of quality of life using standardized questionnaires. Researchers monitor overall survival and progression-free survival for up to 85 months. Safety is closely followed by recording adverse events and treatment discontinuations. The trial aims to provide detailed data on how these treatments affect patients over time and their impact on symptoms and functioning.
Actively Recruiting
Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.
1-10 of 482
1